Neogenomics (NEO) PT Lowered to $17 at BTIG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
NeoGenomics Reports Fourth Quarter and Full Year 2024 Results
February 18, 2025 7:05 AM EST
Full Year Revenue Increased 12% to $661 million;
Ninth Consecutive Quarter of Double-Digit Revenue Growth
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (Nasdaq: NEO) (the Company), a leading oncology testing services company, today announced its fourth-quarter and full year results for the period ended December 31, 2024.
Fourth Quarter and Full Year 2024... More
